Navidea Biopharmaceuticals Announces The Presentation Of Lymphoseek® Data At Upcoming Scientific Meetings In October

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek studies in breast cancer and melanoma are being presented during the month of October at the American Association of Pharmaceutical Scientists meeting in Chicago, IL, the European Association of Nuclear Medicine conference in Milan, Italy and the American Society for Radiation Oncology meeting in Boston, MA. Details of the presentations and posters are listed below.

Conference:		American Association of Pharmaceutical Scientists
Date:		October 14-18, 2012
Location:		Chicago, IL
Poster Title 1:		The Effect of Post-Injection Time Interval of Tc 99m Tilmanocept Injection to In Vivo Probing on Nodal Concordance Rates Relative to Vital Blue Dye in Melanoma and Breast Cancer Patients Undergoing Intraoperative Lymphatic Mapping
Author:		Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date:		Poster Sessions
Poster Title 2:		Sensitivities and False Negative Rates of Tc 99m Tilmanocept and Vital Blue Dye By Time Interval of Tc 99m Tilmanocept Injection to In Vivo Probing in Melanoma and Breast Cancer Patients Undergoing Intraoperative Lymphatic Mapping
Author:		Wendy L. Metz, PhD, Navidea Biopharmaceuticals
Session, Date:		Poster Sessions
Conference:		European Association of Nuclear Medicine
Date:		October 27-31, 2012
Location:		Milan, Italy
Presentation Title 1:		Phase 3 Trials Evaluating Biotargeted (CD206) Tc 99m Tilmanocept Against Vital Blue Dye (VBD) in the Detection of Lymph Nodes (LNs) in Breast Cancer (BC) Patients
Author:		Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date:		Oncology Clinical Science: Sentinel Lymph Node 2 Session
		Sunday, October 28, 2012
Presentation Title 2:		Clinical Performance of Tc 99m Tilmanocept Versus Vital Blue Dye (VBD) in the Detection of Lymph Nodes (LNs) in Melanoma Patients
Author:		Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date:		Oncology Clinical Science: Sentinel Lymph Node 1 Session
		Sunday, October 28, 2012
Conference:		American Society for Radiation Oncology (ASTRO)
Date:		October 28-31, 2012
Location:		Boston, MA
Poster Title:		Exploitation Targeting Of The CD206 Receptor In Lymph Node-Resident Reticuloendothelial Cells With A Novel Synthetic 99mTc-ligand (Tilmanocept) Significantly Enhances Localization In Contrast To 99mTc-Colloid: A New Meta-analysis
Author:		Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date:		Poster Sessions

About Lymphoseek ^®

Lymphoseek ^® (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer, in patients with breast cancer or melanoma.

Lymphatic mapping is a procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Accurate staging of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 229,000 new cases of breast cancer and 76,000 new cases of melanoma are expected to be diagnosed in the United States in 2012.

1 2 Next › Last »